Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.National Cancer Institute investigators have reported a two-thirds decrease in visible metastatic lung nodules using Chemokine Therapeutics' CTCE-9908 in a preclinical bone cancer study.
Subscribe to our email newsletter
The National Cancer Institute (NCI) findings in osteosarcoma, a form of bone cancer, are consistent with a preclinical study of CTCE-9908 conducted by researchers at Chemokine Therapeutics.
CTCE-9908 is designed to inhibit the growth and spread of certain common cancers with the potential for use with existing therapies (chemotherapy, surgery, and radiation) to improve treatment outcomes.
CTCE-9908 is an analog of SDF-1, a chemokine that has been shown to affect the growth and spread of cancer, and an antagonist of SDF-1 receptors, which are expressed in both stem cells and various common cancers.
The presence of these SDF-1 receptors on cancer cells allows the cancerous cells to migrate from the original cancer site to new sites that are rich in SDF-1, such as bone marrow, liver, and lungs, where they develop new blood vessels and form new tumors. CTCE-9908 binds competitively to the receptors on cancer cells, preventing the interaction of SDF-1 with the receptors.